Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Draft Guidances Assert Oversight Over Multiplex Tests

This article was originally published in The Gray Sheet

Executive Summary

CDRH is asserting its oversight authority in the development and use of high-tech tests that may fall through the cracks of current premarket practices via the release of two draft guidances Sept. 7

You may also be interested in...



Test Makers Have One Year To Comply With New ASR Guidelines

Diagnostic test makers will have until September 2008 to comply with newly clarified FDA policies for analyte specific reagents

Test Makers Have One Year To Comply With New ASR Guidelines

Diagnostic test makers will have until September 2008 to comply with newly clarified FDA policies for analyte specific reagents

FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines

FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24

Related Content

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel